Full Press Release Details
Rezolute Announces $30 Million Debt Financing
SLR Capital Partners
REDWOOD CITY, Calif., April 19, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc.
("Rezolute" or "the Company") (Nasdaq: RZLT), a clinical stage biopharmaceutical company dedicated to advancing
targeted therapies for rare and metabolic diseases with serious unmet needs, today announced that it has entered into a $30 million debt financing agreement with investment affiliates managed by SLR
Capital Partners ("SLR"). Fifteen million of the $30 million loan was funded upon closing with
an interest only period of 24 months. The remaining fifteen million may be funded upon Rezolute achieving certain predetermined milestones
"The access to capital provided by this facility gives Rezolute
non-dilutive operational flexibility as we continue advancing our pipeline. Thanks to Armentum Partners in their brokering of this competitive
deal for Rezolute" said Nevan Elam, Rezolute's Chief Executive Officer.
Further information with respect to the debt financing agreement with
SLR will be contained in a Current Report to be filed on Form 8-K by Rezolute with the Securities and Exchange Commission.
About Rezolute, Inc.
Rezolute is advancing targeted therapies for rare, metabolic, and life-threatening
diseases. Its lead product candidate, RZ358, is in Phase 2b development as a potential treatment for congenital hyperinsulinism (HI),
a rare pediatric endocrine disorder. Its pipeline also includes RZ402, an orally available plasma kallikrein inhibitor in Phase 1 development
About SLR Capital Partners
SLR Capital Partners, LLC ("SLR Capital Partners") is an
SEC-registered investment adviser that primarily invests directly in leveraged, U.S. middle market companies in the form of cash flow
and asset-based senior secured investments. SLR Capital Partners manages over $7.5 billion of investable capital, including serving as
the investment adviser to two publicly-traded business development companies, SLR Investment Corp. and SLR Senior Investment Corp. The
SLR Capital Partners' life science finance business provides financing solutions for later-stage bio-pharma, medical device, diagnostics,
healthcare IT and healthcare services companies, both venture-backed private and public, and from pre-revenue clinical to early commercial
stage. For more information, please visit https://www.slrcapitalpartners.com/Financial-Solutions/Life-Science-Finance
Forward-Looking Statements
This release, like many written and oral communications presented by
Rezolute, Inc. and our authorized officers, may contain certain forward-looking statements regarding our prospective performance
and strategies within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934,
as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained
in the Private Securities Litigation Reform Act of 1995 and are including this statement for purposes of said safe harbor provisions.
Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, and expectations of the Company,
are generally identified by use of words such as "anticipate," "believe," "estimate," "expect,"
"intend," "plan," "project," "seek," "strive," "try," or future or conditional
verbs such as "could," "may," "should," "will," "would," or similar expressions. Our
ability to predict results or the actual effects of our plans or strategies is inherently uncertain. Accordingly, actual results may differ
materially from anticipated results. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak
only as of the date of this release. Except as required by applicable law or regulation, Rezolute undertakes no obligation to update these
forward-looking statements to reflect events or circumstances that occur after the date on which such statements were made.